Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Ltd
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus placebo in postmenopausal subjects with advanced or metastatic hormone receptor positive breast cancer
The primary objective of the study is to compare progression free survival (PFS) of treatment with exemestane and pazopanib versus exemestane plus placebo in postmenopausal subjects with hormone rece...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A clinical trial in subjects who suffer from hay fever to see the effects of the study medication, SB-705498, when taken on its own or in conjunction with a background therapy, Fluticasone Propionate, on the symptoms triggered by an allergen challenge chamber session
Effect of 8 day treatment with intranasal SB-705498 on nasal symptoms elicited by an allergen chamber challenge in subjects with allergic rhinitis when co-administered with FP, compared to FP alone. ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
The primary objective of this study is to demonstrate the superiority of 50 mg oral GW679769, in combination with a single 4 mg intravenous dose of ZOFRAN (ondansetron hydrochloride), over a single 4 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to provide continued access of eltrombopag to subjects who are currently participating in a GlaxoSmithKline sponsored investigational study with eltrombopag (parent study)
The objective of this study is to provide continuing treatment with eltrombopag for subjects who are currently participating in a GSK sponsored investigational study of eltrombopag (parent study) an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study of a new medicine, an intravenous antibiotic (GSK2251052) in adults, with complicated intra-abdominal infection
To evaluate the safety and tolerability of GSK2251052 in the treatment of adult subjects with cIAI. To evaluate the clinical and microbiological efficacy of GSK2251052 in microbiologically evaluabl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy
The objective of this 8-week study is to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (200mcg, 400mcg, 600mcg and 800mcg) administered once daily in the evening...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 administered orally as monotherapy for 12 weeks in healthy postmenopausal women with moderate to extremely severe vasomotor symptoms
To evaluate the safety and tolerability of two doses of GSK232802 administered once daily for 12 weeks in healthy postmenopausal women with moderate to extremely severe VMS. To evaluate the effect ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705B in COPD subjects
To assess the safety and tolerability of repeat inhaled doses of GSK233705B (inhaled twice daily for 7 days) in COPD patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures
To demonstrate the ability of eltrombopag, compared to placebo to reduce the proportion of subjects with chronic liver disease and thrombocytopenia (platelets <50,000/μL) who receive platelet transfus...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Study CR9108963: A Dose-Range Finding Study of SB-751689 in Post-Menopausal Women with Osteoporosis
To characterise the dose-response for SB-751689 with respect to safety and efficacy based on BMD and biomarkers of bone turnover to enable dose selection for subsequent studies
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant